



Dr. Patrice Rioux – MD, PhD

Chief Medical Officer at Glycomine, Inc.

Dr. Rioux received his Medical Education at Faculte de Medecine Pitie-Salpetriere, his Ph.D. in Mathematical Statistics at Faculte des Sciences, and his Degree of Pharmacology (pharmacokinetics and clinical pharmacology) at Faculte de Medecine Pitie-Salpetriere.

Dr. Patrice Rioux has been deeply involved in development of drugs for rare diseases for the last 20 years. His background includes development of drugs and biologic products for various indications across neurodegenerative diseases, immunology, pain management, oncology, and metabolic diseases.

He was most recently the Senior Vice-president of Global Clinical Development at ArmaGen, Inc., a company focused on the development of fusion proteins for the treatment of lysosomal storage diseases, and before that, he was the Chief Medical Officer for Raptor Pharmaceuticals, Inc. where he was responsible for securing regulatory approval of a delayed-release cysteamine for the treatment of a lysosomal storage disease, nephropathic cystinosis, in both the U.S. and Europe.

He previously served as Chief Medical Officer at Edison Pharmaceuticals, and as Vice President Clinical at Repligen, where he gained significant orphan disease experience in mitochondrial diseases as well as in autism and auto-immune diseases.

After several years as a clinical researcher at INSERM (France), he started his career in the pharmaceutical industry at Biogen, working on multiple sclerosis, before joining Variagenics, Inc., one of the first pharmacogenomic companies.

(biography obtained from the Glycomine, Inc. website)